Analysis for EW

📈 Growth & Financial Trajectory

EW progressed over 8 quarters from 2024-Q1 to 2026-Q1, with Revenues rising from about $1.41B to $1.65B (roughly +17%). Net income attributable to parent grew from about $351M–$358M to roughly $381M. A 2024-Q3 one-off spike to about $3.06B net income is noted but normalized trends show steady expansion in core profitability. Gross margin remained strong around the mid-to-high 70s%, latest near 78%, and Operating Margin near 29%, indicating robust operating leverage and earnings quality.

💰 Margins & Cash Flow

EW shows margin resilience: Gross Margin ≈ 78% and Operating Margin ≈ 29% in the latest quarter. Operating cash flow has been consistently positive (e.g., around $44M in 2026-Q1 and substantial results in mid-2025), while investing cash flow is regularly negative, reflecting ongoing capital activity. Financing cash flow fluctuates; overall net cash flow remains positive in most periods, underscoring solid liquidity and cash generation capability.

🛡️ Balance Sheet & Liquidity

Balance sheet integrity is evident: total assets around $13–14B, equity near $10–10.3B, and current assets well in excess of current liabilities, indicating ample liquidity. Noncurrent liabilities are modest (roughly $1–1.6B), supporting a comfortable equity cushion and low leverage relative to assets.

⚠️ Key Drivers & Risks

• Drivers: Adoption of transcatheter heart valve technologies (TAVR); durable demand for cardiovascular devices with favorable margin mix.
• Risks: Revenue cyclicality and reimbursement/regulatory shifts; potential for accounting distortions from one-off items in historical periods.